#ORPHAN_DRUGS #DEPARTMENT_OF_PHARMACY #PHARMITIAN_SOCIETY

(2:14)

Canadians Fragmented System for Orphan Drugs

(1:32)

#BREAST_CANCER #PHARMITIAN_SOCIETY #DEPARTMENT_OF_PHARMACY

(1:56)

Orphan Drugs: Costs

(4:44)

FDA Basics: Timothy Cote - Office of Orphan Products Development

(6:38)

How Can Specialty Pharmacies Reduce the Cost of Orphan Drugs?

(40)

Risvodetinib Designated as an Orphan Drug by U.S. FDA.

(2:15)

The Canadian Orphan Drug Act Explained

(3:40)

Orphan Drugs, Exclusivity, and Suing the FDA

(2:56)

Patients Matter: FDA’s Office of Orphan Products Development Grants Programs

(4:45)

Orphan Drug, Rare Pediatric Disease, and Expedited Program Designations Webinar (10/6)

(1:45)

MCG Health: The Future of Orphan Drug Designations \u0026 Drugs for Rare Conditions

(1:9)

Orphan Drugs: Cost vs Benefits

(38)

Commercialising orphan drugs: the pharmaphorum podcast

(17:53)

Dr. Marlene E. Haffner, former Director of the Office of Orphan Products Development at the FDA

(5:8)

How Can Pharmacists Support Patients Being Treated with Orphan Drugs?

(49)

The Orphan Drug Act - How Much Has Changed Since 1983?

(1:39)

Orphan Drugs Bring Hope in the Precision Medicine Era

(58)

What Opportunities for Orphan Drugs Exist in Specialty Pharmacy?

(59)